New Diabetes Drugs in Development

John B. Buse, MD, PhD; University of North Carolina, recently spoke on new drugs in development at the 64th annual American Diabetes Association's Advanced Postgraduate Course.


Almost 300 companies are involved in developing drugs for type 2 diabetes alone, and additional companies are working on type 1 diabetes and diabetes complications. The list below is itemized from his speech.


1.     Drugs already released or coming out soon

 iGlarLixi, a GLP-1 receptor agonist combined with a basal insulin analog, is already available; it is a mixture of glargine and lixisenatide. Soon, liraglutide mixed with insulin degludec will be available as well.


These drug combinations are exceptionally powerful glucose-lowering agents in the setting of type 2 diabetes. They are associated with lower risks for hypoglycemia and less weight gain than with insulin alone.


"The question is whether we eventually will be using those agents exclusively instead of basal insulin, or what their place will be in the therapeutic landscape."

SGLT-2 inhibitors. Ertugliflozin is a new SGLT-2 inhibitor that is under review by the US Food and Drug Administration. It seems to work similarly to the agents we have available now.


Sotagliflozin, an SGLT-1/SGLT-2 dual inhibitor, is another agent that is well advanced into phase 3 trials in patients with type 1 diabetes. This drug has somewhat different properties, and the early results in the setting of type 1 diabetes are quite encouraging. That agent could be available within the next couple of years.


2.     In development

GLP-1 receptor agonists. Intarcia Therapeutics has developed a mini osmotic pump for delivery of exenatide. That pump is about the size of a matchstick. For 6 or perhaps as long as 12 months, it will release a steady stream of exenatide into the circulation, lowering glucose effectively and promoting weight loss, as we expect from GLP-1 receptor agonists. This may be a huge boon to patients who are not very good at taking their medications.


Oral GLP-1 agonistsare in development. Semaglutide is a once-weekly, injected product that is being developed by Novo Nordisk, but a once-daily oral formulation of semaglutide also seems to be very active in glucose lowering and weight loss. That oral formulation is well along in the process of development.


3.     Further out

Glucose-responsive insulin (GRI); it used to be called smart insulin. After this agent is injected, it releases insulin only when the glucose level is high; it does not release insulin when the glucose level is low. "This has worked well in mice, and we are about to begin pig studies." Dr Zhen Gu, an assistant professor in the Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University in Raleigh has invented a patch for delivery of GRI.


4.     New class of medicine

Glucokinase (GK) activatorshave had a checkered past. Development of previous GK activators was halted because of problems with hypoglycemia in some cases, hypertriglyceridemia in some cases, and a loss of efficacy after the first 6 months in other cases.


The newer GK activator, being developed by vTv Therapeutics in High Point, North Carolina, seems to have overcome those barriers. They are designing studies with their GK activator in patients with type 1 diabetes. These studies will begin enrollment in the near future. They also hope to develop this drug for use in type 2 diabetes.


Dr. Buse's practice combines clinical care, research and education. He has received international recognition for innovative clinical care and efforts at prevention of type 1 diabetes, type 2 diabetes and their complications. He practices patient-centered care focusing on developing treatment programs in collaboration with patients that meet their needs and expectations. He works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects focus in novel treatments including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs and developing the evidence-base for treatment guidelines of the future in diabetes care.

I'd like to read more about...

Click to see more or the + to add to your topics of interest

Articles just for you!

Get content tailored just for you through by choosing your topics of interest.

Choose Now >